IP Library › Granted Patent US 10,265,373
Granted Patent B2
US 10,265,373 · App. 13/821,448 · Granted Apr 23, 2019

Pharmaceutical composition and method of treating a microbial infection with sulcotidil

Inventors: Yanmin Hu (London, GB); Anthony R M Coates (London, GB)
Assignee: HELPERBY THERAPEUTICS LIMITED
A61K38/12A61K31/05A61K31/10A61K31/138A61K31/145A61K31/167A61K31/18A61K31/216A61K31/282A61K31/305A61K31/382A61K31/395A61K31/407A61K31/417A61K31/4178A61K31/445A61K31/473A61K31/475A61K31/4709A61K31/4741A61K31/517A61K31/5415A61K31/704A61K31/7052A61K33/24A61K38/14A61K45/06Y02A50/401Y02A50/404Y02A50/406Y02A50/469Y02A50/473Y02A50/475Y02A50/478Y02A50/479Y02A50/481Y02A50/483
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,265,373
App. No.
13/821,448
Granted
Apr 23, 2019
Kind
B2
Abstract

The present invention relates to the use of one or more compounds selected from the following classes of biologically active agents: an a-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator and/or a vitamin, or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection and in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.

Claims (8)

1. A method of killing multiplying, non-multiplying and/or clinically latent microorganisms associated with a bacterial infection which comprises administering to a mammal, including man, suloctidil, or a pharmaceutically acceptable salt thereof.

2. A method of killing multiplying, non-multiplying and/or clinically latent microorganisms associated with a bacterial infection which comprises administering to a mammal, including man, suloctidil, or a pharmaceutically acceptable salt thereof wherein the infection is caused by Staphylococcus aureus , or Escherichia coli.

3. The method according to claim 1 , wherein the infection is caused by Staphylococcus aureus or Escherichia coli.

4. The method according to claim 1 , wherein suloctidil is administered.

5. The method according to claim 2 , wherein suloctidil is administered.

6. The method according to claim 4 or claim 5 wherein the infection is caused by S. aureus.

7. The method according to claim 1 or claim 2 , wherein the infection is caused by Escherichia coli.

8. The method according to claim 6 , wherein the infection is caused by MSSA and/or MRSA.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2013
From: HU, YANMIN; COATES, ANTHONY RM
To: HELPERBY THERAPEUTICS LIMITED
Reel/Frame 030448/0203 →
Priority Claims (1)
GB 1015079.5 · Sep 10, 2010 · national
Continuity (1)
Related Publication 20130243886A1 · Sep 19, 2013
Cited By (1)
US 12,544,336